MiddleBrook's shares dive on equity infusion
This article was originally published in Scrip
Executive Summary
MiddleBrook Pharmaceuticals, a US company focused on developing and commercialising anti-infectives, has failed to find a buyer or partner after a year of searching and has instead entered a deal for a $100 million equity infusion with Equity Group Investments (EGI).